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Background: The discordance between steady-state levels of mRNAs and protein has been attributed to
posttranscriptional control mechanisms affecting mRNA stability and translation. Traditional methods of genome
wide microarray analysis, profiling steady-state levels of mRNA, may miss important mRNA targets owing to
significant posttranscriptional gene regulation by RNA binding proteins (RBPs).
Methods: The ribonomic approach, utilizing RNA immunoprecipitation hybridized to microarray (RIP-Chip),
provides global identification of putative endogenous mRNA targets of different RBPs. HuR is an RBP that binds to
the AU-rich elements (ARE) of labile mRNAs, such as proto-oncogenes, facilitating their translation into protein. HuR
has been shown to play a role in cancer progression and elevated levels of cytoplasmic HuR directly correlate with
increased invasiveness and poor prognosis for many cancers, including those of the breast. HuR has been
described to control genes in several of the acquired capabilities of cancer and has been hypothesized to be a
tumor-maintenance gene, allowing for cancers to proliferate once they are established.
Results: We used HuR RIP-Chip as a comprehensive and systematic method to survey breast cancer target genes
in both MCF-7 (estrogen receptor positive, ER+) and MDA-MB-231 (estrogen receptor negative, ER-) breast cancer
cell lines. We identified unique subsets of HuR-associated mRNAs found individually or in both cell types. Two
novel HuR targets, CD9 and CALM2 mRNAs, were identified and validated by quantitative RT-PCR and biotin pull-
down analysis.
Conclusion: This is the first report of a side-by-side genome-wide comparison of HuR-associated targets in wild
type ER+ and ER- breast cancer. We found distinct, differentially expressed subsets of cancer related genes in ER+
and ER- breast cancer cell lines, and noted that the differential regulation of two cancer-related genes by HuR was
contingent upon the cellular environment.
Background
Over the past decade array technologies have provided
several new means for profiling global changes in gene
expression. The power of DNA microarrays is perhaps
best illustrated in the way it has been used to differenti-
ate treatment responses in patient populations. Indivi-
dualized and targeted therapy for several tumors, based
upon underlying differences at the molecular level
among gene expression profiles, is beginning to replace
the traditional morphological-based treatment paradigm
[1-3]. Genome wide microarray analyses, however, are
inherently flawed since they globally profile the steady-
state levels of mRNA, referred to as the transcriptome.
Cellular protein expression levels, however, do not
directly correlate with steady-state levels of mRNAs. It
is well accepted in the RNA field that there is a poor
correlation between steady-state RNA levels and protein.
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tional control mechanisms affecting mRNA stability and
translation. Steady-state mRNA levels of genes, con-
trolled partially or totally at this level, may be mislead-
ing. Gygi and colleagues have shown that correlation
between mRNA and protein levels could not be pre-
dicted from only mRNA steady-state levels [4]. They
observed that some genes had the same mRNA levels
but protein levels varied more than 20 fold. Conversely,
some proteins were of equal expression but their respec-
tive mRNA level varied by more than 30-fold. They con-
cluded that “transcript levels provide little predictive
value with respect to the extent of protein expression”
[4]. Additionally, Idekar and colleagues have described
similar results for the galactose gene [5].
Although our understanding of transcriptional gene
regulation is advanced, posttranscriptional gene regula-
tion remains largely unexplored. It is becoming clear,
however, that this is an important mode of gene regula-
tion, especially for proinflammatory genes. These genes
appear to be posttranscriptionally regulated by RNA
binding proteins (RBPs) which interact with AU-rich
elements (AREs) in the 3’ untranslated region (UTR) of
mRNAs. Approximately 3,000 human genes contain
AREs, representing 8% of the human genome [6]. Many
of these genes which possess AREs are in areas of tran-
sient biological responses, including cell growth and dif-
ferentiation, immune responses, signal transduction,
transcriptional and translational control, hematopoiesis,
apoptosis, nutrient transport, and metabolism [6,7].
New methodologies have provided global identifica-
tion of in vivo mRNA targets of different RBPs. One of
these, termed the ribonomic approach, involves the
immunoprecipitation of ribonucleoprotein complexes
(RNPs) with antibodies against different RBPs, extrac-
tion of mRNA, and hybridization to microarrays [8-10].
This approach, also referred to as RIP-Chip, enables
investigators to identify groups of posttranscriptionally
regulated mRNAs coordinately controlled by RBPs dur-
ing various biological processes. A new paradigm, the
posttranscriptional operon hypothesis, has been devel-
oped which states that RBPs coordinately regulate the
expression of biologically related molecules [11,12]. This
paradigm is being confirmed by the work of many dif-
ferent laboratories as our understanding of posttran-
scriptional regulation broadens and putative operons are
described [8,13-17]. HuR is an RBP that binds to AREs
of many proto-oncogenes and labile mRNAs. It has
emerged as a key regulatory factor which stabilizes and
translationally enhances its targets mRNAs, and affects
their transport from the nucleus to the cytoplasm
[18-20]. HuR belongs to the ELAV (embryonic lethal
abnormal vision) family found in mammalian cells con-
taining four members: HuR, HuB, HuC, and HuD. HuR
i st h eo n l yu b i q u i t o u s l ye x p r e s s e dm e m b e r .T h eo t h e r
family members are found primarily in the central ner-
vous system and gonadal tissue [18]. Many HuR targets
are cytokines, chemokines, and other early-response
genes [21,22].
Of the hallmarks of cancer originally described by
Hanahan and Weinberg, HuR has been demonstrated to
control expression of genes in multiple areas of malig-
nant transformation [23]. Consequently, HuR has been
suggested to function as a tumor maintenance gene, per-
missive for malignant transformation, tumor growth, and
perhaps metastasis [24]. HuR has been described in the
literature as controlling the expression of many cancer-
relevant genes, including those that encode these pro-
teins: Prothymosin-a, Bcl-2, Mcl-1, SirT1, TGF-b, MMP-
9, MTC-1, uPA, VEGF-a,H I F 1 - a and cyclins A1 (CCN
A1), B1 and D1 [25-35]. Increased levels of HuR have
been associated with a more aggressive breast cancer and
a worse prognosis [36-38]. Of significance, HuR has been
described as posttranscriptionally regulating the expres-
sion of many breast cancer relevant genes including
those that encode Glut-1, ERa, COX-2, IL-8, Cyclin E1,
and most recently BRCA-1 [36,39-44]. HuR RIP-Chip
analysis has recently identified Thrombospondin 1 as a
key HuR target in the MCT-1 transformed estrogen
receptor positive (ER+) cell line MCF-7 [45]. Its interac-
tions, however, are complex and, at times, HuR may
interact with miRNAs such as Let-7 to translationally
suppress the expression of C-MYC mRNA [46].
Since HuR has been described as regulating the
expression of many cancer relevant genes, we asked
whether it may coordinately regulate breast cancer
genes in ER+ and ER- breast cancer. We performed a
HuR RIP-Chip analysis on MDA-MB-231 (ER-) and
MCF-7 (ER+) cell lines to identify cancer-relevant genes,
not known to be regulated by HuR, and potential novel
breast cancer targets. Our studies indicated that HuR
was associated with unique subsets of mRNAs in each
cell line as well as a subset of HuR associated mRNA
targets common to both. We chose two cancer-asso-
ciated genes, CD9 and CALMODULIN 2 (CALM2),
highly expressed in both cell lines, and functionally vali-
dated the role of HuR in regulating their expression.
Unexpectedly, HuR differentially regulated the same tar-
get, CD9, in both cell lines in an opposite manner.
Moreover, we found presumptive differential regulation
of CALM2 by HuR, as HuR interacted only with
CALM2 mRNA, but not with family members CALM1
and CALM3 mRNAs. We discovered that HuR interacts
with many breast cancer-relevant genes not previously
known to be controlled by HuR, and target genes which
have not been shown to be cancer related. This latter
category may indeed represent novel cancer genes dis-
covered by HuR RIP-Chip analysis.
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Cells in culture
The MDA-MB-231 (MB-231) and MCF-7 cell lines were
obtained from American Type Culture Collection (Man-
assas, VA). The cell lines were maintained at 37°C in a
humidified atmosphere of 95% air and 5% CO2. MB-231
cells were grown in RPMI (GIBCO®, Invitrogen™, Carls-
bad, CA) containing 10% fetal calf serum (Hyclone,
T h e r m oF i s h e rS c i e n t i f i c ,W a l t h a m ,M A ) ,0 . 5m ML -
glutamine (GIBCO®), 25 mg/ml glucose (Sigma-Aldrich),
HEPES (GIBCO®) and sodium pyruvate (GIBCO®).
MCF-7 cells were grown in DMEM (GIBCO®) supple-
mented with 10% fetal calf serum.
HuR Immunoprecipitations (RIP-Chip)
HuR RIP-Chip was performed as previously described
[8,47,48]. Briefly, lysates were prepared from exponen-
tially growing MB-231 and MCF-7 cells. Equal amounts
of protein lysates were used (100-300 μg). HuR mono-
clonal antibody 3A2 (made in our laboratory from the
3A2 hybridoma, generously provided by Dr. Joan Steitz,
Yale University, New Haven, CT), or isotype control
IgG1 (BD Biosciences, San Jos e ,C A ) ,w e r ep r e - c o a t e d
onto Protein A Sepharose beads (PAS) and extensively
washed. Lysates from each cell initially were pre-
absorbed with 30 μg of IgG1 and then removed by addi-
tion of PAS beads. Individual pull-downs were per-
formed at 4°C for only 1-2 hr to minimize potential re-
assortment of mRNAs.
RNA amplification
The entire amount of recovered RNA per immunopreci-
pitation was amplified using the WT-Ovation™ Pico
RNA Amplification System protocol (NuGen, San Car-
los, CA). Forty ng of total RNA was used as starting
material to generate at least 6 μg of cDNA. Amplified
cDNA was purified using Zymo Research Clean and
Concentrator™-25 (Zymo Research, Orange, CA). Three
μg of amplified and purified cDNA was incubated at 50°
C for 30 minutes with 5 μl of UNG buffer and 5 μl
UNG enzyme and 60 minutes with 5 μl labeling buffer
and 5 μl ARP (biotin) solution as described in NuGen’s
labeling protocol for the Illumina BeadArray platform.
All samples (total RNA, amplified cDNA, and biotin
labeled amplified cDNA) were quantitated using a
Nanodrop™ (Thermo Fisher Scientific, Waltham, MA)
spectrophotometer. RNA quality and integrity were
assessed on selected samples with the Experion™ auto-
mated electrophoresis system (Bio-Rad, Hercules, CA).
Microarray
Biotin-labeled, amplified cDNA (1.5 μg) was hybridized
to a Sentrix® Human-6 v.2 Whole Genome Expression
BeadChips (Sentrix Human WG-6; Illumina, San Diego,
CA). Each chip tested 6 samples and contained 47,293
gene targets, representing 18,025 distinct RefSeq genes
that are not pseudogenes. A total of 3 chips were used
for this experiment. The chips were hybridized at 48°C
for 20 hr in the hybridization buffer provided by the
manufacturer. After hybridization, the chips were
washed and stained with streptavidin-C3. The chips
were scanned on the BeadArray Reader, as described by
Illumina at http://www.illumina.com. The Illumina
BeadStudio software was used to assess fluorescent
hybridization signals.
Quantitative RT-PCR
Selected genes were validated by quantitative RT-PCR.
Briefly, cDNA was generated from the same samples as
previously described for the microarray experiments
using 10 ng total RNA and the SuperScript™ III Plati-
num® Two-Step qRT-PCR Kit with SYBR® Green (Invi-
trogen Carlsbad, CA). RT-PCR was performed on the
StepOne™ Real-Time PCR System (Applied Biosystems,
Foster City, CA). Each sample was run in triplicate for
these genes and the cDNA was divided equally per reac-
tion in a 20 μl volume. The PCR conditions were: 50°C
for 2 minutes and 95°C for 2 minutes, followed by 40
cycles of 95°C for 15 seconds alternating with 60°C for
30 seconds. Melting curve analysis was performed on
every reaction to confirm a single amplicon. For each
cell line, differences in gene expression were determined
using the equation 2
-ΔΔCt,w h e r et h eCt value for either
the HuR or IgG IP was subtracted from the Ct value of
the GAPDH control to yield the ΔCt value. For each cell
line, the ΔCt value for the HuR and IgG IP were com-
puted in triplicate and averaged to give one ΔΔCt value
per sample. Primers used:
Human RT GAPDH Forward 5’ AGCCTCAAGAT-
CATCAGCAATGCC 3’
Reverse 5’ TGTGGTCATGAGTCCTTCCACGAT 3’
Human RT HuR Forward 5’ ATGAAGACCA-
CATGGCCGAAGACT 3’
Reverse 5’ AGTTCACAAAGCCATAGCCCAAGC 3’
Human RT CD9 Forward 5’ TCAGACCAAGAG-
CATCTTCGAGCA 3’
Reverse 5’ ACCAAGAGGAAGCCGAAGAACAGT 3’
Human RT CALM2 Forward 5’ CTGACCAACT-
GACTGAAGAGCAGA 3’
Reverse 5’ TTCTGTGGGATTCTGCCCAAGAG 3’
Cloning strategy of HA HuR
Hemagglutinin (HA) tagged human HuR was cloned
into the NheI and XhoI sites of the pZeoSV2 (-) vector
(Invitrogen). The plasmids were sequenced in both
directions to confirm identity. Cells were transfected
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Lipofectamine 2000 (Invitrogen). After five days trans-
fected media was removed and replaced with fresh med-
ium containing 200 μg/ml of Zeocin antibiotic
(Invitrogen). Cells were selected for a ten day period.
After ten days, the selected cells were maintained in 50
μg/ml of Zeocin to maintain pZeo HA HuR and empty
vector expression. No viable cells remained in the
untransfected well. Cells were then cloned by limiting
dilution.
Lentiviral RNAi HuR knock-down
In order to knockdown HuR, PSICOOLIGOMAKER
v1.5 http://web.mit.edu/ccr/labs/jacks/was used to
identify optimal shRNAs sequences to HuR. We tested
multiple sequences and chose GGATCCTCTGGCA-
GATGT, identified and designated shRNA H760.
Annealed sense and antisense DNA (Integrated DNA
Technologies, Inc, IDT, Coralville, IA), along with stem
loops to create hairpin, were cloned into the HpaI and
XhoI restriction sites in the Lentilox pll3.7 vector
(ATCC). After sequence verification, lentivirus was
packaged in 293FT cells using ViraPower™ Lentiviral
Expression Systems (Invitrogen) following manufac-
turer’s protocol. Both MB-231 and MCF-7 cells were
seeded at a density of 100,000 cells in 100 mm tissue
culture plates with 10 ml of media. The following day
lentivirus, expressing either GFP and no shRNA (empty
lentilox control) or GFP and HuR shRNA H760, was
added at a multiplicity of infection (MOI) of 10 along
with polybrene (8 μg/ml) (Sigma-Aldrich Corp, St.
Louis, MO). After five days, cells were harvested by
trypsinization and sorted for GFP expression using BD
FACSDiva (BD Bioscience). Cells were cloned by limit-
ing dilution and GFP expression was assessed using
FACScan (BD Bioscience) and CellQuest software (BD
Bioscience). GFP expression was >98% and indicated
homogenous cell population.
SDS-PAGE and Western Blot Analysis
Western analysis was performed as described previously
with slight modifications [47]. Briefly, cells were har-
vested and lysed in triple-detergent RIPA buffer with
protease inhibitor cocktail (Roche, Pleasanton, CA). For
nuclear and cytoplasmic fractionation, the NE-PER kit
was used (Pierce, Rockford, IL). Protein quantity was
determined by Bradford Assay. Forty μgo fp r o t e i nw a s
electrophoresed on a 12% SDS-polyacrylamide gel and
transferred to a nitrocellulose membrane. The mem-
brane was blocked with 5% nonfat milk at room tem-
perature for 1 hr and incubated with anti-b-tubulin (1
μg/ml, Sigma-Aldrich) at 4°C overnight. After washing,
the membrane was incubated with monoclonal anti-
HuR clone 3A2 antibody (1 μg/ml) at room temperature
for 1 hr, or anti-CD9 antibody (1:100) (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) at 4°C overnight. The
secondary antibody used was sheep anti-mouse Ig horse
radish peroxidase (1:4000) (GE Healthcare, Piscataway,
NJ), incubated at room temperature for 1 hr. Specific
proteins were detected using chemiluminescence (GE
Healthcare). HuR knock-down was determined to be
>90% using Bio-Rad’s Quantity One software (Bio-Rad)
normalizing to b-tubulin, and HuR over-expression was
quantitated in a similar manner.
Biotin Pull-down
Biotinylated transcripts were synthesized using cDNA
that was prepared from MB-231 cells. Templates were
prepared using forward primers that contained the T7
RNA polymerase promoter sequence (CCAAGCTTC-
TAATACGACTCACTATAGGGAGA [T7]). Primers
used for the preparation of biotinylated transcripts span-
ning the CD9 CR, and 3’UTR (NM_001769) and
CALM2 CR and 3’UTR (NM_001743.3) were as follows:





CALM2 CR 72-515: [T7] GCTGACCAACTGACT-
GAAGA and CTTTGCTGTCATCATTTGTACAAA
CALM2 3’UTR 518-1128: [T7] AGACCTTGTACA-
GAATGTGTTAA and GGGTAAATTGTAATTTTT-
TTATTGGAA
GAPDH 3’UTR: [T7] CCTCAACGACCACTTTGTCA
and GGTTGAGCACAGGG TACTTTATT
The PCR-amplified fragments were purified and used
as templates for in vitro synthesis of the corresponding
biotinylated RNAs by MAXIscript kit (Ambion®, Applied
Biosystems). Biotin pull-down assays were performed by
incubating 40 μg of MB-231 cell lysates with equimolar
of biotinylated transcripts for 1 hr at room temperature.
The complexes were isolated using paramagnetic strep-
tavidin-conjugated Dynabeads (Dynal®, Invitrogen), and
bound proteins in the pull-down material were analyzed
by Western blotting using an antibody recognizing HuR
(Santa Cruz). After secondary-antibody incubations, the
signals were visualized by chemiluminescence (Amer-
sham Biosciences, GE Healthcare).
Statistical Analysis of Microarray Data
Analysis of microarray gene expression data was primar-
ily performed using the Linear Models for Microarray
Data (limma) package [49] and the lumi package [50],
available through the Bioconductor project [51] for use
with R statistical software [52]. After data pre-processing
was completed (Appendix), the statistical analysis was
performed using moderated t-statistics applied to the
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gene using an Empirical Bayes approach [53]. Three
contrasts of interest were computed and tested. The
first was the difference between HuR pull-down and IgG
background for the MB-231 cell line. Genes which
exhibited significantly greater expression in the pull-
down were considered to be in the HuR pellet for the
MB-231 cell line. The second contrast was similar to
the first, but for the MCF-7 cell line. The third and
most important contrast was the difference between the
first and second contrast, and can be viewed as a test of
statistical interaction between HuR and cell line. For a
given gene, this term can be interpreted as reflection of
the synergistic relationship between HuR and estrogen
in breast cancer. Adjustment for multiple testing was
made using the false discovery rate (FDR) method of
Benjamini and Hochberg [54] with an FDR of 10% as
our cutoff for declaring significance. To facilitate inter-
pretation, log fold changes were transformed back to
fold change on the data scale (fluorescent intensity).
Gene ontology (GO) analyses were carried out on the
list of significant genes based on the third contrast
described above. The purpose of the analyses was to test
the association between Gene Ontology Consortium
categories [55] and differentially expressed HuR pellet
genes between MB-231 and MCF-7. Using our defined
gene universe (Appendix), GOstats [56] was used to
carry out conditional hypergeometric tests. These tests
exploit the hierarchical nature of the relationships
among the GO terms for conditioning [57]. We carried
out GO analyses for over-representation of biological
process (BP), molecular function (MF), and cellular
component (CC) ontologies, and computed the nominal
hypergeometric probability for each GO category. These
results were used to assess whether the number of
selected genes associated with a given term was larger
than expected under the null hypothesis, and a p-value
cutoff of 0.01 was used. GO categories containing less
than 10 genes from our gene universe were not consid-
ered to be reliable indicators, and are not reported.
Results
HuR immunoprecipitation from ER+ and ER- breast cancer
cell lines
We first determined HuR protein expression levels in
breast cancer cell lines. HuR is expressed in both the
ER- and the ER+ cell lines, MB-231 and MCF-7, respec-
tively (Figure 1A). RNA immunoprecipitation, using
HuR monoclonal antibody 3A2, recovered HuR (Figure
1A) and revealed, by quantitative RT-PCR, a significant
enrichment of up to fifteen fold for a known HuR tar-
get, b-ACTIN mRNA, as compared to isotype control
(IgG1) and normalized to a non-target, GAPDH mRNA
(Figure 1B). These data showed that HuR RIP
specifically immunoprecipitate HuR protein and asso-
ciated mRNAs, though absolute quantitative conclusions
cannot be drawn since different amounts of lysates were
used and efficiency of immunoprecipitation from differ-
ent cell lines may differ.
RIP-Chip from ER+ and ER- breast cancer cell lines
identifies unique sets of associated mRNAs
RIP-Chip was performed on cytoplasmic lysates from
both breast cancer cell lines with HuR antibody and iso-
type control in order to determine HuR associated
mRNAs. Each immunoprecipitation was done at least
three independent times with matching controls. Signals
from isotype control were subtracted out. Recovered
mRNA was amplified and hybridized to Illumina Sentrix
Human arrays consisting of 47,000 genes. Figure 2
represents a composite array generated by combining
hybridizations to twelve different arrays (log2 scale).
Three groups of HuR-associated target genes were iden-
tified: MB-231 targets in the left upper quadrant; both
MB-231 and MCF-7 targets in the right upper quadrant;
MCF-7 targets in the right lower quadrant. As expected,
most of the mRNAs did not associate with HuR and
were located in the lower left quadrant. There were 395
a n d6 4a n n o t a t e dg e n e s ,a tl e a s t2f o l do rm o r e
enriched, associated with either MB-231 or MCF-7 cells,
respectively, and 182 genes associated with both cell
lines. A complete list can be found in Additional File 1,
Figure S2. The raw data files are available in the NCBI
database at the following link: http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?token=pdsnrqmiawukql-
m&acc=GSE17820, NCBI Accession number
GSE17820). These genes generally fell into three groups.
Group 1 consisted of cancer-associated genes which
were known HuR targets, such as PTMA mRNA. Group
2 consisted of genes which played a role in cancer but
were not known to be HuR targets. Group 3 consisted
of genes with an unknown function in cancer, but
which may be regulated by HuR. These data revealed
that HuR was associated with distinct subsets of
mRNAs in ER+ and ER- breast cancer cells.
Gene Ontology (GO) analyses of differentially expressed
significant genes between ER+ and ER- cells were cate-
gorized into Biological Process (BP), Cellular Compo-
nent (CC), and Molecular Function (MF). GO analyses
allow for the identification of gene families that may
play significant roles related to these categories in
expression profiles. Most of the differentially expressed
genes (155) were found to be more abundant than
expected in 14 BP categories (Figure 3A). Three MF
categories consisted of 100 genes with most of these
(83) related to protein binding and transcription activa-
tor activity. The CC categories contained the least (34)
and were primarily associated with the Golgi apparatus.
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Page 5 of 15Figure 1 Immunoprecipitation and RIP in MB-231 and MCF-7 breast cancer cells. Immunoprecipitations were performed from MB-231 or
MCF-7 cell lysates using anti-HuR monoclonal antibody (3A2) and IgG1 isotype control. A. IP Western of HuR revealed expected size band as
detected by 3A2. Panel on right reveals amounts of HuR in lysates used from both cell lines. B. Verification by quantitative RT-PCR showed
fifteen and eleven fold enrichments of B-ACTIN, a known HuR target, in the 3A2 IPs from MB231 and MCF-7, respectively. All ΔΔCT values were
normalized to GAPDH. Experiments were done in duplicate (n = 2).
Figure 2 HuR RIP-CHIP identifies distinct genetic profiles in ER+ and ER- breast cancer cells. HuR immunoprecipitations were performed
from MB-231 or MCF-7 cell lysates using HuR antibody and IgG1 isotype control hybridized to Illumina Sentrix arrays (47,000 genes). Control
signals were subtracted. Results represent cumulative data from 12 different arrays. Experiments were done in triplicate (n = 3) for each cell line
with matching controls. Scales are log2.
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Table S1. In Table S1 we list the top HuR associated
mRNAs in the different categories which were approxi-
mately 5 fold enriched or greater. As can be seen in Fig-
ure 3B, a partial listing of some of these genes (in bold)
are candidate members to multiple areas of cancer con-
trol, as suggested by Hanahan and Weinberg. We note
that though b-ACTIN mRNA was amongst the most
abundant of HuR-associated mRNAs in MCF-7 cells, b-
ACTIN mRNA levels were only 3.93-fold higher in HuR
IP compared to IgG IP in MB-231 cells. Therefore,
since this was less than the 5-fold cut-off we employed
for Table S1, it is not listed. Thus, these results may
have identified novel HuR-controlled genes which may
play roles in breast carcinogenesis in a cancer subtype-
specific fashion.
Validation of HuR targets CD9 and CALM2 by real-time
PCR and biotin pull-down analyses
In order to validate HuR binding to genes identified in Fig-
ure 2, we chose two known cancer associated genes, CD9
and CALM2, highly expressed in both cell lines. Two inde-
pendent approaches confirmed the physical interaction
between HuR, CD9 and CALM2 mRNAs. Precipitated
mRNA from the RIP-Chip experiments were analyzed by
quantitative RT-PCR. Both CD9 and CALM2 mRNAs
were enriched in the HuR RIP by as much as 160 fold
(Figures 4A and 4B), but not the isotype control IP. We
Figure 3 GO Classification of genes found by RIP CHIP of potential HuR targets and their relationship to the Acquired Capabilities of
Cancer Model. A. Differentially expressed genes which are more represented in the Biological Processes (BP) GO category than expected. B.
Original representation showing subsets of transcripts found to be targets of association with HuR (normal type). New transcripts found in this
study with RIP-Chip (bold type). Enhanced expression upon binding to HuR influences several of the acquired capabilities of cancer cells
described by Hanahan and Weinberg [23,24].
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mRNAs by biotin pull-downs. The relevant portion of the
mRNA was transcribed with biotin tags and incubated
with lysates from the two cell lines to probe for interac-
tions with protein. The mixture was then separated by
pull-down using streptavidin-coated beads and HuR levels
were analyzed by Western blot analysis. As seen in Figure
5, HuR specifically interacts with CD9 and CALM2
mRNAs in the 3’UTR regions, but not within the coding
region (CR) or with a control biotinylated RNA corre-
sponding to the 3’UTR of the housekeeping control
GAPDH mRNA, which is not a target of HuR.
HuR differentially regulates CD9 and CALM2 in MB-231
and MCF-7 cell lines
To gain insight into the biological effects of these asso-
ciations, we studied the consequences of stably increas-
ing or decreasing HuR abundance. Individual MB-231
clones which over- and under-express HuR were estab-
lished by limiting dilution (Figure 6A and 6B). MB-231
cells over-expressed HuR by about 140% (Figure 6A).
HuR knock-down using lentiviral shRNA resulted in
~95% reduction in HuR expression (Figure 6B). Surpris-
ingly, over-expression of HuR in MB-231 cells caused
decreases in both CD9 protein and mRNA levels
Figure 4 Validation of target CALM2 and CD9 mRNAs by quantitative RT-PCR. Quantitative RT-PCR using cell lysates, HuR antibody, and
IgG1 from RIP-CHIP analysis confirmed results identifying CALM2 mRNA (A) and CD9 mRNA (B) as HuR targets. Change in gene expression is
represented as fold increase in HuR immunoprecipitation as compared to IgG1. GAPDH mRNA was used as an endogenous control. Error bars
represent SEM. p value is < 0.005. Experiments were done in triplicate (n = 3).
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resulted in increases in both CD9 mRNA and protein
levels (Figures 6C and 6E). This is the opposite of what
we predicted, since HuR is generally regarded as a stabi-
lizer of mRNA. In contrast, over-expression of HuR in
MB-231 cells did not significantly alter the levels of
CALM2 mRNA (Figure 6D). Figure 6F depicts a graphi-
cal analysis which reveals that HuR over-expression
decreases both CD9 mRNA and protein levels, as com-
pared to controls (dashed line set at 100%). Whereas,
HuR shRNA knock-down results in increases in both
CD9 mRNA and protein levels above control levels.
We performed similar analyses with MCF-7 cells,
though the over-expression levels of HA HuR were only
approximately 10%, since this was a pooled population
(we have been unable to obtain MCF-7 clones which
over-express HuR). In contrast, we generated MCF-7
clones with reduced HuR levels (93%) using lentiviral
shRNA (Figure 7B). Western blot analysis of MCF-7
cells with over-expression of HuR reveals modest
increases in CD9 protein levels (Figure 7C). There are
also modest decreases in CD9 p r o t e i ne x p r e s s i o ni n
MCF-7 with reduced HuR levels (Figure 7C). mRNA
levels of CD9 and CALM2 are essentially unchanged in
MCF-7 cells which over-express HuR (Figure 7D). As
expected, HuR knock-down in MCF-7 cells using lenti-
viral shRNA resulted in significant reductions in both
CD9 and CALM2 mRNA levels (Figure 7E). The right
panel in Figure 7E indicates efficiency of HuR mRNA
knock-down which is consistent with the protein data
(Figure 7B). These results are summarized in Figure 7F.
There are no significant changes seen in CD9 mRNA
Figure 5 Biotin Pull-down of CD9 and CALM2.A . Scheme of Coding region (CR) and 3’UTR fragments for biotin pull-down assay. The
sequences were obtained from Entrez data base. CR and 3’UTR fragments selected for amplification by PCR are as noted. B. 1% agarose gel
electrophoresis showing PCR amplified products of the coding regions and 3’UTR’s for CD9 (442 bp and 432 bp, respectively) and CALM2 (443
bp and 610 bp, respectively). C. Biotin pull-down assay using lysates prepared from MB-231 cells. The binding of HuR to biotinylated 3’UTR
transcripts from both CD9 and CALM2 mRNAs was specific. HuR did not bind a biotinylated control (GAPDH 3’UTR); and did not bind to
biotinylated transcripts spanning the CR of CD9 or CALM2. Experiments were done in duplicate (n = 2).
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Page 9 of 15and CD9 protein for HuR over-expression. There is a
more pronounced knock-down, however, in CD9 mRNA
in MCF-7 cells with reduced HuR levels.
The results of HuR shRNA knock-down in MCF-7 cells
were as expected, but opposite of those seen for MB-231
cells. Steady-state mRNA levels of CD9 and CALM2
mRNAs decreased, consistent with the hypothesis that
HuR generally stabilizes its mRNA targets. One possible
explanation of these disparate results is different levels of
total cellular or cytoplasmic HuR. We performed nuclear
and cytoplasmic fractionation (Additional File 3, Figure
S3). These results demonstrated modest (approximately
10%) greater cytoplasmic levels of HuR in MB-231 cells
as compared to MCF-7. The total cellular HuR levels are
very similar for both MB-231 and MCF-7 cells. Taken
together, these results indicated that HuR appeared to
differentially regulate the same mRNAs in a manner
dependent upon the cellular milieu.
Figure 6 HuR differentially regulates CD9 and CALM2 in MB-231. A. Epitope HA tagged HuR is over-expressed by 142% and 138%
respectively, in stably transfected clones 4E1 and 5F1, as compared to empty vector (EV) control clone 2C7. B. HuR knock-down using lentiviral
short hairpin (sh) RNA H760 results in a 94% reduction in steady state levels of protein in clone A7 (LL = lentilox control). C. HuR over-expression
results in a 40% reduction in CD9 protein levels as assayed by Western analysis; however, HuR knock-down using lentiviral shRNA results in an
increase from 100% to 228% of CD9 levels. D. Over-expression of HuR decreases CD9 mRNA levels but not CALM2 expression. Analysis of steady
state CD9 and CALM2 mRNA levels by quantitative RT-PCR reveals significant decreases in CD9 mRNA levels, whereas CALM2 levels are
unaffected. Although CALM2 expression appears greater, the change is not significant. E. Knocking down HuR levels by shRNA in MB-231 cells
shows significant increases in CD9 and CALM2 mRNA levels by quantitative RT-PCR. Decreased levels of HuR mRNA validate HuR shRNA knock-
down. F. Graph showing the effects of HuR on the expression of CD9 mRNA. HuR over-expression results in decreases in both mRNA and
protein levels, though the decreases are greater in RNA. Whereas, HuR knock-down by shRNA results in significant increases at both the mRNA
and protein levels, with greater change at transcript levels. The dashed line represents levels in control cells. Error bars represent SEM. p value is
< 0.005; N.S. = not statistically significant; * = statistically significant. All experiments were done in triplicate (n = 3).
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We utilized RIP-Chip technologies to define differentially
regulated HuR genes in ER+ and ER- breast cancer. To
our knowledge, this is the first report of a side-by-side
genome-wide comparison of HuR-associated targets in
wild type ER+ and ER- breast cancer cells. Our findings
indicated that HuR interacts with small subsets of genes
in breast cancer, out of the possible 8% of human genes
possessing AREs which are potential HuR targets. Three
broad categories of HuR targets were identified. First,
there was a subset of targets only found in ER+ breast
cancer. Second, there was a unique subset of HuR targets
found only in ER- breast cancer. A third subset consisted
of HuR-associated mRNAs common to both forms of
breast cancer, many of which were previously described
as having roles in cancer.
We selected and validated two HuR targets, CD9 and
CALM2 mRNAs, which were found in high abundance in
both types of breast cancer. Initially, we employed the pre-
viously developed “heat map” signature of HuR binding to
Figure 7 Effects of over-expressing or reducing HuR on CD9 and CALM2 expression in MCF-7 cells. A. Western analysis of HuR over-
expression in heterogenous population of cells reveals approximately 10% over-expression. B. Lentiviral HuR shRNA efficiently knocks down HuR
protein by over 90%. C. HuR over- expression and under-expression results in small changes in CD9 protein levels in MCF-7 cells. D. Levels of
both CD9 and CALM2 mRNAs are unchanged in cells which over-express HuR; whereas lentiviral knock-down of HuR in MCF-7 cells results in
decreases in steady-state mRNA levels (E). The graph in (F) shows minimal changes in CD9 mRNA and protein levels in HuR over-expressing
MCF-7 cells. The CD9 mRNA levels, however, are more affected in HuR knock-down. P value is < 0.005; N.S. = not statistically significant; * =
statistically significant.
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binding was verified by HuR immunoprecipitations, and
analyzed by quantitative RT-PCR and biotin pull-downs.
Both CD9 and CALM2 mRNAs were enriched in HuR
RIPs compared to isotype control IP reactions. Biotin pull-
downs verified the binding of HuR protein specifically to
the 3’UTR regions of both mRNAs, as had been predicted.
CD9 is a tetraspanin molecule which plays important roles
in cellular development, activation, growth and motility. It
has been implicated in a variety of cancers, including but
not limited to gastric cancers and B cell acute leukemia
[58-60].
The role of CALM2 in cancer is less well understood
but may be linked to cancer since it is involved in con-
trolling calcium signaling [61,62]. There are three CAL-
MODULIN genes (CALM1, CALM2 and CALM3) highly
expressed in both MB-231 and MCF-7 cell lines (Addi-
tional File 4, Figure S1). Interestingly, although they are
encoded by different genes at different chromosomal
locations, all three encode the same open reading frame
but differ in the 5’ and 3’ UTRs [[61,63], and [64]]. Only
CALM2 mRNA interacts with HuR by RIP analysis.
Moreover, previously published reports have indicated
the necessity of knocking down all three CALMODULIN
mRNAs by siRNA to achieve knock-down of the protein
[ 6 1 ] .W ec o n c l u d et h a tt h e r em a yb ed i f f e r e n t i a lH u R
associated regulation of these CALMODULIN genes in
breast cancer, even though the mechanism needs to be
further delineated.
Surprisingly, the regulation of both CD9 and CALM2
target genes was dependent upon the cellular milieu. To
test the functional consequences of HuR binding to
these two transcripts, we prepared cells that stably
expressed higher or lower HuR, compared to the parent
cells, in both ER+ and ER- breast cancer cell lines. HuR
appears to differentially regulate the expression of CD9
in opposite directions in the two different forms of
breast cancer. Specifically, HuR over-expression in ER-
breast cancer (MB-231) paradoxically decreased CD9
mRNA and protein levels, whereas HuR knock-down
increased the CD9 m R N Al e v e l s .T h i si st h eo p p o s i t eo f
what is predicted for most HuR targets, since HuR is
thought to stabilize its mRNA targets and often
increases their translation. There did not seem to be
similar effects upon CALM2 expression. As expected,
knock-down of HuR by shRNA decreased expression of
CD9 and CALM2 in ER+ breast cancer (MCF-7).
Though there are differences in cytoplasmic HuR levels
in MB-231 cells as compared with MCF-7, these are
modest (10%). This is in keeping, however, with obser-
vations that MB-231 cells are more undifferentiated and
more aggressive.
Moreover, analysis of HuR-associated mRNAs in both
ER+ and ER- breast cancer revealed three broad
categories of genes. First, there were well known cancer
genes, such as PTMA, which are regulated by HuR [27].
Second, there were cancer-related genes, such as CD9
and CALMODULIN, which were not known to be HuR
regulated until this report. Third, there were other
genes identified by HuR association with unknown can-
cer function. These could potentially represent novel
cancer targets. Additional proof of HuR involvement
with other known cancer genes, such as CD44 and
GATA-3, may represent novel insights into the mechan-
isms of regulation of these cancer targets (see Additional
Files). These results may therefore advance the field by
shedding insights into posttranscriptional regulation of
known and perhaps unknown cancer target genes.
Though the exact mechanisms of HuR differential reg-
ulation of CD9 and CALM2 are presently unclear, it
may involve microRNA (miRNA) regulation. In a recent
report, we described the recruitment by HuR of miRNA
let-7 to translationally silence C-MYC expression [46]. It
is clear from the findings of laboratories headed by Fili-
powicz, Steitz and other investigators, that RBPs and
miRNAs are involved in intricate associations to affect
downstream translational suppression or activation of
target mRNAs to help meet cellular needs [65,66]. Sharp
and colleagues proposed that different interactions
between RBPs and miRNAs may have evolved as a pro-
tective mechanism for the cell against environmental
stress [67].
A remaining question is why HuR selectively binds to
certain genes containing AREs. Our previous work has
demonstrated the role that HuR plays in myogenesis by
stabilizing the expression of three critical genes involved
in myogenesis: MYOD, MYOGENIN,a n dp21
cip1 [68].
HuR over-expression results in precocious muscle differ-
entiation and HuR siRNA knock-down prevents muscle
differentiation [69]. It is highly probable that there are
more than three HuR targets inside these cells. A speci-
fic phenotype potentially arises when HuR levels are
altered which may involve interactions with miRNAs,
although this theory needs to be fully investigated.
Our findings share some similarity to earlier reports of
HuR RIP-Chip analysis of MCF-7 cells stably transfected
with MCT-1 [45]. These analyses, however, were not gen-
ome-wide and employed transfected cells. Nevertheless,
thrombospondin, a known important anti-angiogenic fac-
tor, was identified as a HuR-regulated target. Combined
with earlier reports of the role of HuR in regulating,
VEGF-a and HIF1a, HuR may be controlling a “posttran-
scriptional mini-operon” involved in angiogenesis
[29,32,70]. Further studies are being conducted in our
laboratory to investigate the role of HuR in breast cancer
angiogenesis using xenograft animal models. It will be par-
ticularly important to test the role of HuR upon CD9 and
CALM2 expression in breast tumors in vivo.
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being appreciated as a driver of malignant transforma-
tion. The roles of both RBPs and miRNAs (so-called
oncomirs) are being recognized in cancer [71]. Many
reports have described alterations in miRNA expression
profile and function as contributing to breast cancer
malignant transformation and metastasis [72-75]. HuR
RIP-Chip analysis may shed further light into malignant
breast cancer transformation by identifying HuR asso-
ciated mRNAs.
We believe that there are potential applications for
tamoxifen resistance as well. Keen and colleagues have
described a potential mechanistic link between HuR
expression and tamoxifen drug resistance [76]. As breast
cancer cells acquire tamoxifen resistance, there are
increased levels of cytoplasmic HuR expression.
Increased cytoplasmic HuR levels have previously been
described in situations where HuR actively influences
expression of cytoplasmic targets [18,47,48]. Drug resis-
tance could be reversed by using siRNA to knock-down
HuR expression, whereas exogenous over-expression of
HuR could cause cells to become resistant to tamoxifen.
We therefore propose that HuR may be coordinately
regulating genes which may allow a cell to acquire
tamoxifen resistance. It will be interesting to further
investigate HuR-associated target genes in ER+ cells in
this light.
Conclusion
In summary, using RIP-Chip analysis, we have per-
formed for the first time a genome-wide comparison of
HuR-associated targets in wild type ER+ and ER- breast
cancer. We have identified novel HuR targets and have
gained insight into the role HuR plays in regulating
known cancer genes. We found distinct, differentially
expressed subsets of HuR cancer related genes in ER+
and ER- breast cancer cell lines. Based on our observa-
tions, the enhanced expression of these mRNA subsets
by HuR can influence many of the acquired capabilities
of cancer cells. Further investigation into HuR’sr o l ei n
regulating these genes may provide novel insights into
breast cancer diagnosis and therapy.
Appendix
Microarray Data Preprocessing
Data quality was examined by looking at quality controls
metrics produced by Illumina’s software (BeadStudio
v3.1.3.0, Gene Expression Module 3.2.7). The data were
then exported for further analyses in R. Image plots of
each array were examined for spatial artifacts, and there
was no evidence of systematic effects indicative of tech-
nical problems with the arrays. Within limma, quantile
normalization was used for between chip normalization.
Finally, quality control statistics were computed using a
variety of Illumina’s internal control probes that are
replicated on each array. Any probes which were consid-
ered “not detectable” across all samples were excluded
from further statistical analyses in order to reduce false
positives. The determination of “not detectable” was
based upon the BeadStudio computed detection p-value
being greater than 1%.
Gene Ontology Gene Universe
In defining the gene universe for the analysis, non-speci-
fic filtering was used to increase statistical power with-
out biasing the results. We started with all probes on
the Illumina array which had both an Entrez gene iden-
tifier [77] and a GO annotation, as provided in the lumi-
HumanAll.db [78] annotation data package and GO.db
[79] annotation maps (built using data obtained from
NCBI on 4/2/08). This set was then reduced by exclud-
ing probes that exhibited little variability (interquartile
range (IQR) of <0.1 on log2 scale) across all samples
because such probes are generally not informative.
Finally, for probes that mapped to the same Entrez iden-
tifier, a single probe was chosen in order to insure a
surjective map from probe IDs to GO categories (via
Entrez identifiers). This was necessary to avoid redun-
dantly counting GO categories which produces false
positives. Probes with the largest IQR were chosen to be
associated with an Entrez identifier.
Additional file 1: Figure S2. Table of complete GO analysis. Listing of
HuR-associated genes with odds ratios and functional categories.
Additional file 2: Table S1. HuR targets five fold or greater. Listing of
HuR-associated mRNAs in MB-231 and MCF-7 cell lines.
Additional file 3: Figure S3. Total cellular levels of HuR are similar
in MB-231 and MCF-7 cells. Nuclear and cytoplasmic separation was
performed to measure levels of HuR in different compartments of MB-
231 and MCF-7 cells. Total cellular HuR levels were very similar, whereas
there was a small (10%) increase in HuR cytoplasmic levels in MB-231
cells as compared to MCF-7. Absence of b-tubulin staining demonstrates
integrity of isolation as there should not be b-tubulin in the nuclear
fraction. Bands were measured by densitometry and normalized to b-
tubulin controls. (T = total cellular lysate; C = cytoplasmic lysate, N =
nuclear lysate).
Additional file 4: Figure S1. Relative baseline values of CALM1,
CALM2, CALM3, and CD-9 mRNAs in ER+ and ER- cells. Quantitative
RT-PCR performed on mRNA extracted from cell lysates showing relative
levels of CALM1, CALM2, CALM3, and CD-9 mRNAs in MB-231 and MCF-7
breast cancer cells. All values were normalized to GAPDH mRNA. All
experiments were done in triplicate (n = 3) except for CALM3 (n = 2).
Abbreviations
(ER-): Estrogen receptor negative; (ER+): estrogen receptor positive; (RIP):
RNA immunoprecipitation; (RIP-Chip): RNA immunoprecipitation applied to
microarrays; (3’ UTR): 3’ untranslated region; ELAV1: (embryonic lethal
abnormal vision 1).
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